FAST and ASF have joined a powerful coalition of organizations urging Congress to pass the FY26 Defense Appropriations Act and restore full funding for the Department of Defense’s medical research programs, including the Congressionally Directed Medical Research Programs (CDMRP).
This is especially critical for the Angelman syndrome community because thanks to the efforts of our Advocates in DC, Angelman syndrome is listed as an eligible condition for federal funding through the Peer Reviewed Medical Research Program (PRMRP). Failure to pass this bill—or cuts to the funding—could mean losing hard‑won federal funding that supports AS science and future potential therapies.
By signing this letter, FAST and ASF are working to protect the progress our community has made and to keep Angelman syndrome research moving forward.